- Remove All
- Your shopping cart is currently empty
Human LILRA3, also known as Leukocyte Ig-like receptor 4 (LIR-4), CD85 antigen-like family member E, Immunogobulin-like transcript 6 (ILT-6) and monocyte inhibitory receptor HM43/HM31, is a 70 kD Ig superfamily member that belongs to the leukocyte receptor complex/cluster. Mature LILRA3 is 416 amino acids (aa) in length and contains four C2-type Ig-like domains. Unlike other LILR family members, LILRA3 is actively secreted.LILRA3 acts as soluble receptor for class I MHC antigens. LILRA3 binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1 or LILRB2. Binds with high affinity to the surface of monocytes, leading to abolish LPS-induced TNF-alpha production by monocytes.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μg | $418 | 7-10 days | |
500 μg | $1,670 | 7-10 days | |
1 mg | $2,800 | 7-10 days |
Biological Activity | Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
Description | Human LILRA3, also known as Leukocyte Ig-like receptor 4 (LIR-4), CD85 antigen-like family member E, Immunogobulin-like transcript 6 (ILT-6) and monocyte inhibitory receptor HM43/HM31, is a 70 kD Ig superfamily member that belongs to the leukocyte receptor complex/cluster. Mature LILRA3 is 416 amino acids (aa) in length and contains four C2-type Ig-like domains. Unlike other LILR family members, LILRA3 is actively secreted.LILRA3 acts as soluble receptor for class I MHC antigens. LILRA3 binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1 or LILRB2. Binds with high affinity to the surface of monocytes, leading to abolish LPS-induced TNF-alpha production by monocytes. |
Species | Human |
Expression System | HEK293 Cells |
Tag | C-His-Avi |
Accession Number | Q8N6C8 |
Synonyms | LIR-4HM43e3,LIR4,LILRA3,ILT-6,ILT6,HM43,HM31,CD85e |
Construction | Gly24-Glu439 |
Protein Purity | > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
Molecular Weight | 47.9 kDa (predicted). Due to glycosylation, the protein migrates to 68-72 kDa based on Tris-Bis PAGE result. |
Endotoxin | < 1 EU/μg by the LAL method. |
Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4).Typically, 8% trehalose is incorporated as a protective agent before lyophilization. |
Reconstitution | Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
Stability & Storage | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping | In general, Lyophilized powders are shipping with blue ice. |
Research Background | Human LILRA3, also known as Leukocyte Ig-like receptor 4 (LIR-4), CD85 antigen-like family member E, Immunogobulin-like transcript 6 (ILT-6) and monocyte inhibitory receptor HM43/HM31, is a 70 kD Ig superfamily member that belongs to the leukocyte receptor complex/cluster. Mature LILRA3 is 416 amino acids (aa) in length and contains four C2-type Ig-like domains. Unlike other LILR family members, LILRA3 is actively secreted.LILRA3 acts as soluble receptor for class I MHC antigens. LILRA3 binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1 or LILRB2. Binds with high affinity to the surface of monocytes, leading to abolish LPS-induced TNF-alpha production by monocytes. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.